Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis Mariane Gonçalves Martynychen Canan, Caroline Souza Sokoloski, Carolina Rossetti Severo, Samia Zahi Rached, Rodrigo Abensur Athanazio

Experience With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Disease Laura Carrasco Hernández, Rosa Mª Girón Moreno, Mari Nieves Balaguer Cartagena, Adrián Peláez, Amparo Sole, Antonio Álvarez Fernández, Almudena Felipe Montiel, Casilda Olveira, Gabriel Olveira, Ainhoa Gómez Bonilla, Beatriz Gómez Crespo, Marta García Clemente, Marta Solís García, Joana Quaresma Vázquez, Enrique Blitz Castro, Jesús Rodríguez González, Andrea Expósito Marrero, Laila Diab-Cáceres, Cristina Ramos Hernández, Ester Zamarrón de Lucas, Concha Prados Sanchez, Marina Blanco Aparicio, Alejandro López Neyra, Verónica Sanz Santiago, Carmen Luna Paredes, Isabel Delgado Pecellín, Óscar Asensio de la Cruz, Esther Quintana Gallego

Immune-Mediated Hepatocellular Injury Induced by Elexacaftor/Tezacaftor/Ivacaftor Therapy Cindy Stephania Aponte Guevara, Ester Zamarrón De Lucas, María Concepción Prados Sánchez